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Abstract 
Toll-like receptor 2 (TLR2) recognizes cell-wall components of Staphylococcus aureus, 
which colonizes more than 90% of atopic eczematous skin lesions. The regulatory 
mechanisms of TLR2 signaling in the skin remain unclear. Allergin-1, an inhibitory 
immunoglobulin-like receptor containing an immunoreceptor tyrosine-based inhibitory 
motif (ITIM), is expressed on mast cells (MCs) and inhibits IgE-mediated anaphylaxis 
in mice. Here, we show that Allergin-1 inhibits TLR2-mediated activation of, and 
inflammatory cytokine production by, MCs in vitro. Compared with wild-type mice, 
Allergin-1-deficient mice showed enhanced ear swelling with enhanced collagen 
deposition and greater Ly6G
+
 neutrophil recruitment after intradermal injection of 
Pam2CSK4 into pinnae. Using Mas–TRECK mice, which is a MC-deletion system 
based on il4 enhancer elements, we also demonstrated that Allergin-1 on MCs is 
responsible for the Pam2CSK4-induced ear swelling. These results suggest that 
Allergin-1 on skin MCs suppresses TLR2-induced dermatitis.  
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Introduction 
Mast cells (MCs) play pivotal roles in allergic reactions in barrier tissues, including skin 
(1). MCs are activated through both immunoglobulin E (IgE)-dependent and 
-independent pathways to express various Toll-like receptors (TLRs), which recognize 
diverse components of pathogens and initiate host defense mechanisms (2). Among 
TLRs, TLR2 is the predominant receptor for Staphylococcus aureus, which colonizes 
more than 90% of atopic eczematous skin lesions (3). Although TLR2 ligand is known 
to activate MCs (4), the regulation of TLR2 signaling in MCs remains incompletely 
understood.    
 Allergin-1, an immunoglobulin-like receptor bearing an immunotyrosine-based 
inhibitory motif (ITIM) in its cytoplasmic region, is highly expressed on MCs. We 
previously reported that Allergin-1 recruits the SH2-containing tyrosine phosphatases 
SHP-1 and SHP-2, which inhibits high-affinity receptors involved in IgE 
(FcεRI)-mediated signaling and subsequent MC activation, and thus suppresses 
IgE-mediated systemic and cutaneous anaphylaxis in mice (5). Because SHP-1 and 
SHP-2 downregulate TLR-mediated production of proinflammatory cytokines (6,7), we 
hypothesized that Allergin-1 might influence TLR2-mediated signaling. Here, we 
examined whether Allergin-1 suppresses Pam2CSK4-induced TLR2 signaling in the 
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MCs of mice.  
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Methods 
Mice 
Wild-type (WT) C57BL/6N mice were purchased from Clea Japan (Tokyo, Japan). 
Allergin-1-deficient (Allergin-1
–/–
) mice were generated in our laboratory, as previously 
described (5). Mas–TRECK mice on a C57BL/6 background have been described 
previously (8). All experiments used female mice (age, 8 to 13 weeks) that were bred in 
the specific pathogen-free facilities at the University of Tsukuba, and all procedures 
followed the guidelines of the animal ethics committee of the University of Tsukuba. 
 
Cells and qualitative PCR analysis 
Bone-marrow–derived cultured MCs (BMMCs) were prepared from mice as described 
(5) and stimulated with 1 μg/ml Pam2CSK4 (InvivoGen, San Diego, CA, USA). Total 
RNA was isolated from cell pellets (TRIzol, Thermo Fisher Scientific, Waltham, MA, 
USA) and used as a template for reverse-transcription reactions (High-Capacity cDNA 
RT Kit, Applied Biosystems, Foster City, CA, USA). Real-time PCR analysis of Il6, 
Tnfsf2, Il1b, and Gapdh (measured as an internal control for normalization of data) was 
performed by using an ABI7500 sequence detector (Applied Biosystems) and Power 
SYBR Green PCR Master Mix (Applied Biosystems). The primers were: Il6 (forward, 
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5′-gaggataccactcccaacagacc-3′; reverse 5′-aagtgcatcatcgttgttcataca-3′), Tnfsf2 
(5′-gggccaccacgctcttc-3′; 5’-ggtctgggccatagaactgatg-3′), Il1b 
(5′-actcaactgtgaaatgccacc-3′; 5′-tgatactgcctgcctgaagc-3′), and Gapdh 
(5′-tggtgaaggtcggtgtgaac-3′; 5′-atgaaggggtcgttgatggc-3′). mRNA transcript levels were 
determined relative to that in the unstimulated WT BMMCs. All experiments were 
performed in triplicate. 
 
Antibodies 
Anti-mouse Allergin-1 (TX83; mouse IgG1) was described previously (5). TX83 was 
biotinylated with Biotinylation Kit (Sulfo-OSu; DOJIN, Tokyo, Japan). Monoclonal 
antibodies (mAbs) to mouse c-Kit (ACK45), Ly6C (AL-21), CD11c (HL3), Siglec-F 
(E50-2440), and CD16/32 (2.4G2) were purchased from BD Biosciences (San Jose, CA, 
USA). Anti-mouse CD45.2 (104), FcεRIα (MAR1), and CD11b (M1/70) were 
purchased from eBioscience (San Diego, CA, USA) Anti-mouse Ly6G (1A8) was 
purchased from TONBO Biosciences (San Diego, CA, USA). Anti-Gr-1 (RB6-8C5) 
hybridoma provided by Dr. Kazumasa Ogasawara (Shiga University of Medical 
Science) was used for neutrophil depletion.  
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Cytometric bead array analysis 
The concentrations of various inflammatory cytokines and chemokines were measured 
by using cytometric bead array analysis (BD Biosciences) according to the 
manufacturer’s instructions. 
 
Pam2CSK4-induced dermatitis model 
TLR2 ligand-induced dermatitis model was reported previously (9). The left pinnae of 
WT, Allergin-1
-/-
, diphtheria toxin (DT; Sigma-Aldrich, St Louis, MO, USA)-treated 
Mas-TRECK, and DT-treated Mas-TRECK mice intradermally injected with 1×10
6
 WT 
or Allergin-1
-/-
 BMMCs 5 weeks previously were sensitized by intradermal injection of 
Pam2CSK4 (4 µg). Neutrophil-depleted mice were generated by intraperitoneal 
injection of anti-Gr-1 (RB6-8C5, 50 μg) mAb on days -2, -1, +1, +3, and +5 and were 
injected intradermally with Pam2CSK4 (4 μg) on day 0. Ear thickness at 3 sites was 
measured daily by using a micrometer; these 3 measures were averaged and reported as 
the average ear thickness after treatment.  
 
Flow cytometry 
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Ears were treated with enzyme mixture containing collagenase IV and DNase I (300 
U/ml and 50 U/ml, respectively; Worthington Biochemical, Lakewood, NJ) for 1 h at 37 
o
C with shaking. Cells were treated with anti-CD16/32 mAb to avoid binding to FcR 
on ice for 10 minutes prior to incubation with the indicated combination of Abs. Stained 
cells were acquired on BD LSR Fortessa (BD Biosciences) and analyzed using Flowjo 
software (Treestar, Inc., San Carlos, CA). 
 
Histology 
Ears were fixed in 10% formalin and were embedded in paraffin. Ear sections were 
stained with hematoxylin-eosin (HE) or with Masson’s trichrome (MT). For analysis of 
epidermal and collagen-deposited dermal thickness, randomly selected regions in the 
specimen were measured by using a fluorescent microscope (BZ-X710; Keyence) and 
its associated software. Epidermal and collagen-deposited dermal thicknesses were 
expressed as mean ± s.e.m μm of ear skin. 
 
Statistics 
Statistical analyses were performed with the unpaired Student’s t-test. P values <0.05 
were considered statistically significant. 
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Results and discussion 
To investigate the role of Allergin-1 in the TLR2-triggered production of inflammatory 
cytokines, we used the TLR2/TLR6-binding diacylated lipopeptide Pam2CSK4 to 
stimulate BMMCs derived from WT or Allergin-1-deficient mice. Quantitative RT-PCR 
analysis showed that the mRNA expression of Il1b, Tnfsf2, and Il6 was significantly 
higher in Allergin-1-deficient BMMCs than in WT BMMCs at 2 h after stimulation with 
Pam2CSK4 (Fig 1A). Notably, Il1b expression in Allergin-1-deficient BMMCs was 
approximately 20 times that in WT BMMCs (Fig 1A). Consistent with these results, 
Allergin-1-deficient BMMCs produced more TNF-α and IL-6 than did WT BMMCs 
(Fig 1B).  
 Because Allergin-1 suppressed the Pam2CSK4-induced production of neutrophil 
chemoattractants, including IL-6, TNF-α, and IL-1β, which promote the immune 
defense against S. aureus infections (10,11), we next tested whether Allergin-1 inhibits 
TLR2 signaling-mediated dermatitis. Pam2CSK4 was injected intradermally into the 
left pinnae of WT or Allergin-1-deficient mice, and ear swelling was measured daily 
thereafter. Ear swelling in WT mice peaked at day 4 and subsequently declined; in 
contrast, swelling on day 1 was greater in Allergin-1-deficient mice than in WT mice 
and remained elevated throughout the study (Fig 2A). In addition, the Ly6G
+
 neutrophil 
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population in ear tissue 1 day after Pam2CSK4 injection was greater in 
Allergin-1-deficient mice than in WT mice (Fig 2B). Histological analysis demonstrated 
that epidermal thickness was comparable between WT and Allergin-1-deficient mice at 
8 days after the intradermal injection of Pam2CSK4 (Fig 2C). However, we observed 
that Allergin-1-deficient mice exhibited significantly greater amount of collagen 
deposition, as analyzed by staining with Masson’s trichrome, than did WT mice (Fig 
2D). Although TNF-α, IL-6 and IL-1β are reported to promote fibrosis (12), increased 
production of these cytokines in response to Pam2CSK4 injection might be involved in 
augmented ear swelling in Allergin-deficient mice. Further analyses are required to 
clarify whether this is also the case.  
 After we had confirmed that Allergin-1 is expressed on skin-resident myeloid 
cells, including FcεRI+c-Kit+ MCs, CD11b+ cells, Langerin+ cells, and Ly6G+ 
neutrophils (Fig. 3A), we investigated whether Allergin-1 on MCs contributes to 
Pam2CSK4-induced ear swelling. For this we used Mas–TRECK mice, which carry a 
DT-inducible MC deletion system that incorporates Il4 enhancer elements (8). Flow 
cytometry analysis confirmed the lack of MCs in ear tissue after the injection of DT in 
Mas–TRECK mice (Fig. 3B and C). Skin MCs in DT-treated Mas–TRECK mice were 
reconstituted through intradermal injection of either WT or Allergin-1-deficient 
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BMMCs (Fig. 3B). Pam2CSK4-induced ear swelling in DT-treated Mas–TRECK mice 
reconstituted with WT BMMCs was similar to that of their non-reconstituted 
counterparts (Fig. 3D). However, ear swelling was more severe in DT-treated mice 
reconstituted with Allergin-1-deficient BMMCs than in those reconstituted with WT 
BMMCs (Fig. 3D). These results indicate that Pam2CSK4-induced MC activation was 
specifically inhibited by Allergin-1 in skin.  
To examine whether neutrophils were involved in the increased 
Pam2CSK4-induced ear swelling in Allergin-1-deficient mice, WT and 
Allergin-1-deicient mice were injected with anti-Gr-1 mAb to deplete neutrophils. 
Allergin-1-deficient mice still showed significantly more severe ear swelling than did 
WT mice after injection with Pam2CSK4 even after neutrophil depletion (Fig 3E), 
indicating that neutrophils were not involved in the increased Pam2CSK4-induced ear 
swelling in Allergin-1-deficient mice. Moreover, both DT-treated and DT-untreated 
Mas–TRECK mice showed significantly increased neutrophil recruitment after injection 
with Pam2CSK4 (Fig 3F), suggesting that Allergin-1-expressing cells such as CD11b
+
 
cells, rather than MCs, might be responsible for Pam2CSK4-induced neutrophil 
recruitment in ear tissue. Together, these results suggest that although Allergin-1 on 
MCs plays an important role in suppression of Pam2CSK4-induced ear swelling, 
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neutrophils are dispensable for the increased Pam2CSK4-induced ear swelling in 
Allergin-1-deficient mice.  
  The importance of ITIM domains in shaping TLR2-mediated immune 
responses is demonstrated by the finding that the ITIM-bearing receptors PIR-B and 
CEACAM-1 directly interact with the pathogens S. aureus and Moraxella catarrhalis, 
respectively (13,14). Although pathogens frequently utilize ITIM-containing receptors 
to evade immune detection, the ITIM-bearing receptors that downregulate TLR2 
signaling to maintain host homeostasis are largely unknown. We found here that 
Allergin-1 on MCs specifically inhibited TLR2-ligand–induced dermatitis in mice.  
 Allergin-1 is also expressed at high level on myeloid cells, including CD11b
+ 
cells 
and neutrophils (Fig 3A). CD11b
+
 cells consist of dendritic cell (DC) and 
monocytes/macrophages lineages that strongly express TLR2 (15). The recruitment of 
neutrophil in response to Pam2CSK4 might be induced by CD11b
+
 cells in DT-treated 
Mas–TRECK mice. Therefore, Allergin-1 may also inhibit TLR2 signaling in CD11b+ 
cells as well, and Allergin-1 on MC and CD11b
+
 cells may cooperate to promote 
TLR2-mediated inflammation in vivo.  
 The ligand for Allergin-1 remains undetermined. However, since a fusion protein 
consisting of extracellular domain of mouse Allergin-1 and Fc portion of human IgG1 
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bound to BMMC (unpublished observation), it is possible that the Allergin-1 ligand 
might be expressed on MC and cis- or trans-interaction of Allergin-1 to the ligand on 
MC may transmit inhibitory signal via Allergin-1 in MC.   
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Figure Legends 
Figure 1. Allergin-1 inhibits Toll-like receptor (TLR) 2 signaling in 
bone-marrow–derived cultured mast cells (BMMCs) from mice. (A) Quantitative 
reverse transcription–polymerase chain reaction (RT-PCR) analyses of proinflammatory 
cytokine expression by BMMCs at 2 h after stimulation with Pam2CSK4 (1 μg/ml). (B) 
Cytometric bead array analyses of proinflammatory cytokine production by BMMCs at 
24 h after stimulation with Pam2CSK4 (10 μg/ml). WT, C57BL/6N mice; KO, 
Allergin-1-deficient mice; GADPH, glyceraldehyde 3-phophate dehydrogenase (used as 
an internal control for normalization). *, P < 0.05; **, P < 0.01; ***, P<0.005. 
 
Figure 2. Loss of Allergin-1 exacerbates TLR2-ligand–induced dermatitis. 
(A) The left pinnae of C57BL/6N wild-type (WT, n=15) and Allergin-1 knockout (KO, 
n=14) mice were immunized intradermally with Pam2CSK4 (4 µg), after which ear 
swelling was measured. Data are reported as the means ± SEM of 4 independent 
experiments. (B) Frequency of CD45.2
+
Ly6G
+
CD11b
+
neutrophils in ear skin at 1 day 
after id injection of Pam2CSK4. Hematoxylin-Eosin (HE) staining (C) and Masson’s 
trichrome staining (MT) (D) of the ear skin at 8 days after id injection of Pam2CSK4. 
Epidermal thickness (C) and collagen deposition (D) was evaluated as mean + s.e.m. 
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per mm of ear pinna. *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P<0.001. 
 
Figure 3. Reconstitution of skin MCs in diphtheria toxin (DT)-treated 
Mas–TRECK mice. (A) FACS analysis demonstrated Allergin-1 expression on 
skin-resident MCs (CD45.2
+
PI
-FcεRI+c-Kit+), eosinophils (CD45.2+PI-Siglec-F+), 
neutrophils (CD45.2
+
PI
-
CD11b
+
Ly6G
+
), CD11b
+
 cells (CD45.2
+
PI
-
CD11b
+
Ly6G
-
), and 
Langerin
+
 cells (CD45.2
+
PI
-
CD11b
+
I-Ab
+
Langerin
+
). Black lines indicate WT 
C57BL/6N mice; gray lines represent Allergin-1 KO mice. (B) The experimental design 
for reconstitution of skin MCs in DT-treated Mas–TRECK mice. (C) FACS detection of 
reconstituted MCs in skin at 5 weeks after intradermal injection of BMMCs in 
DT-treated Mas–TRECK mice. (D) Left ear pinnae of WT or Allergin-1-deficient 
BMMC-reconstituted DT-treated Mas–TRECK mice were injected with Pam2CSK4, 
after which ear swelling was measured. (E) Neutrophil-depleted mice were generated by 
i.p. injection of anti-Gr-1 mAb on days -2, -1, +1, +3, and +5 and were injected 
intradermally with Pam2CSK4 on day 0, after which ear swelling was measured. (F) 
DT-treated or -untreated Mas–TRECK mice were i.d. injected with Pam2CSK4. 
Frequency of CD45.2
+
Ly6G
+
CD11b
+
 neutrophils in ear skin at 1 day after injection was 
determined by flow cytometry analysis. Data are reported as the means ± SEM of 2 
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independent experiments. *, P < 0.05; **, P < 0.01; ****, P<0.001. 
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